Tag:
Erbitux
Latest Headlines
Latest Headlines
Top 10 Best-selling Cancer Drugs in 2011
Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development.
Idera's troubled TLR program founders in PhII cancer study
This morning the biotech highlighted just how problematic the field is when it announced that the lead drug in that pact--IMO-2055--failed a mid-stage study in advanced head and neck cancer.
CEO: Roche would consider more money-back deals
Roche expanded in the realm of pay-for-performance pricing with a recent deal on Avastin . If German patients don't respond, hospitals and public insurers in that country will get their money back,
NICE votes nay for Lucentis, cancer meds; yea for Eliquis
As usual when the U.K. cost-effectiveness watchdogs convene, the latest NICE meeting delivered some newsworthy decisions. Perhaps the most notable: Eliquis , from Bristol-Myers Squibb ( $BMY ) and
Two old drugs eyed as new brain tumor treatment
Two cancer drugs used for other indications may help beat back a common malignant brain tumor resistant to current therapies, scientists from the U.S. and South Korea have found. They made their drug
Keeping FLEXible, EGFR predicts lung cancer survival
Patients with advanced non-small-cell lung cancer (NSCLC), the most common form of lung cancer, don't have many options for treatment and tend not to have a long life expectancy. According to results
Merck KGaA tries again on Erbitux for lung cancer
If at first you don't succeed, try again with a smaller patient group. That's the approach Merck KGaA is taking with Erbitux, after losing one bid to broaden use of the drug to lung cancer patients.
Avastin, Erbitux rack up data gains
As the big European cancer meeting wrapped up, more data is coming out. Today's crop of info on existing drugs focuses mostly on breast and ovarian cancer, with some good news on both fronts. Eli
Merck KGaA sifts through Erbitux safety data
Merck KGaA is taking its magnifying glass to the data on Erbitux safety. That's because European regulators, in reviewing and rejecting the drug for lung cancer earlier this month, uncovered an
Erbitux looks for narrower lung-cancer use
Germany's Merck KGaA hasn't given up on Erbitux for lung cancer. It's sifting clinical data to identify patient subgroups that benefit most from the treatment, the company's pharma chief told
